Stephen Betz Biography and Net Worth

Stephen F. Betz, Ph.D., is a co-founder of Crinetics and was Vice President of Biology from December 2009 to October 2021 and currently serves as our Chief Scientific Officer. In addition, Dr. Betz is a member of the scientific advisory board of Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications.

Earlier in his career, Dr. Betz was Director of Endocrinology and Metabolism at Neurocrine Biosciences, Inc., where he worked on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. Prior to Neurocrine, from 2001 to 2003, he led laboratory efforts at GeneFormatics, Inc., and from 1996 to 2000, he worked in pharmaceutical discovery at Abbott Laboratories, including structure-guided drug design, assay development, and compound screening in the Research Nuclear Magnetic Resonance Group.

What is Stephen F. Betz's net worth?: The estimated net worth of Stephen F. Betz is at least $3.68 million as of September 10th, 2024. Dr. Betz owns 68,576 shares of Crinetics Pharmaceuticals stock worth more than $3,675,674 as of December 21st. This net worth estimate does not reflect any other assets that Dr. Betz may own. Additionally, Dr. Betz receives an annual salary of $672,660.00 as Insider at Crinetics Pharmaceuticals. Learn More about Stephen F. Betz's net worth.
How old is Stephen F. Betz?: Dr. Betz is currently 58 years old. There are 4 older executives and no younger executives at Crinetics Pharmaceuticals. The oldest executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who is 61 years old. Learn More on Stephen F. Betz's age.
What is Stephen F. Betz's salary?: As the Insider of Crinetics Pharmaceuticals, Inc., Dr. Betz earns $672,660.00 per year. The highest earning executive at Crinetics Pharmaceuticals is Dr. R. Scott Struthers Ph.D., Founder, President, CEO & Director, who commands a salary of $978,340.00 per year. Learn More on Stephen F. Betz's salary.
How do I contact Stephen F. Betz?: The corporate mailing address for Dr. Betz and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Stephen F. Betz's contact information.
Has Stephen F. Betz been buying or selling shares of Crinetics Pharmaceuticals?: Stephen F. Betz has not been actively trading shares of Crinetics Pharmaceuticals in the last ninety days. Most recently, Stephen F. Betz sold 1,035 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $51.50, for a transaction totalling $53,302.50. Following the completion of the sale, the insider now directly owns 68,576 shares of the company's stock, valued at $3,531,664. Learn More on Stephen F. Betz's trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Richard Struthers (CEO), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, insiders at the sold shares 33 times. They sold a total of 554,549 shares worth more than $26,112,214.05. The most recent insider tranaction occured on November, 22nd when COO Jeff E Knight sold 501 shares worth more than $28,316.52. Insiders at Crinetics Pharmaceuticals own 6.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 11/22/2024.

Stephen F. Betz Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/10/2024	Sell	1,035	$51.50	$53,302.50	68,576
8/26/2024	Sell	3,000	$53.19	$159,570.00	69,611
7/25/2024	Sell	3,000	$53.43	$160,290.00	75,611
7/10/2024	Sell	3,000	$48.55	$145,650.00	78,611
6/10/2024	Sell	3,000	$43.86	$131,580.00	83,643
5/28/2024	Sell	3,000	$47.49	$142,470.00	86,643
5/10/2024	Sell	3,000	$49.43	$148,290.00	89,643
1/25/2024	Sell	3,000	$37.26	$111,780.00	73,298
1/10/2024	Sell	3,000	$37.65	$112,950.00	76,298
12/26/2023	Sell	3,000	$35.89	$107,670.00	79,298
12/11/2023	Sell	3,000	$32.87	$98,610.00	82,298
11/27/2023	Sell	3,000	$31.84	$95,520.00	85,298
1/25/2023	Sell	8,336	$21.07	$175,639.52	67,815
1/17/2023	Sell	3,126	$18.00	$56,268.00	76,151
12/15/2022	Sell	3,126	$16.00	$50,016.00	82,403
12/1/2022	Sell	3,126	$17.84	$55,767.84	84,968
11/15/2022	Sell	3,126	$18.72	$58,518.72	88,094
10/17/2022	Sell	3,126	$17.73	$55,423.98	94,346
10/3/2022	Sell	3,126	$19.64	$61,394.64	97,472
9/15/2022	Sell	4,168	$21.01	$87,569.68	100,598
9/7/2022	Sell	1,042	$21.00	$21,882.00	104,766
5/2/2022	Sell	3,247	$20.10	$65,264.70	107,598
4/18/2022	Sell	5,664	$25.81	$146,187.84	110,845
4/4/2022	Sell	9,000	$23.97	$215,730.00	116,509
3/31/2022	Sell	4,164	$21.06	$87,693.84
3/1/2022	Sell	3,123	$19.73	$61,616.79
2/1/2022	Sell	3,123	$18.79	$58,681.17
1/18/2022	Sell	4,168	$23.29	$97,072.72
1/3/2022	Sell	7,168	$28.02	$200,847.36
12/28/2021	Sell	3,000	$27.95	$83,850.00
12/15/2021	Sell	5,668	$24.14	$136,825.52
12/1/2021	Sell	5,668	$27.38	$155,189.84
11/8/2021	Sell	3,900	$28.42	$110,838.00
11/5/2021	Sell	12,600	$27.95	$352,170.00
11/1/2021	Sell	5,668	$24.79	$140,509.72
10/27/2021	Sell	3,000	$24.00	$72,000.00
10/21/2021	Sell	1,042	$21.10	$21,986.20

Stephen F. Betz Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $53.60

$51.73

$54.25

50 Day Range

MA: $57.04

$52.09

$60.69

2 Week Range

Now: $53.60

$33.67

$62.53

Volume

1,940,449 shs

Average Volume

780,930 shs

Market Capitalization

$4.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Stephen Betz Biography and Net Worth

What is Stephen F. Betz's net worth?

How old is Stephen F. Betz?

What is Stephen F. Betz's salary?

How do I contact Stephen F. Betz?

Has Stephen F. Betz been buying or selling shares of Crinetics Pharmaceuticals?

Who are Crinetics Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Crinetics Pharmaceuticals?